Cash from Zimmer certainly not received in half (hence why revenue grew so much yet little movement in cash). Likely for Convatec too.
Zimmer are reported to have bought only 2 months of product … if this forecast is correct, I would think Q3 revenue growth would likely be flat (but more cash) then growth again in Q4. If optimistic … revenue will dip. Revenue growth from direct channel needs to accelerate beyond US$100K/qrt. By my guestimates Xperience sales are <US$2,000 per surgeon per qrt at this stage.
Cash from Zimmer certainly not received in half (hence why...
Add NXS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.5¢ |
Change
-0.015(10.0%) |
Mkt cap ! $39.44M | |||
| Open | High | Low | Value | Volume |
| 15.5¢ | 15.5¢ | 13.5¢ | $119.9K | 836.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 28579 | 13.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.0¢ | 24827 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| NXS (ASX) Chart |